Drug discovery is a complex, time-intensive process that requires researchers to navigate vast amounts of scientific literature, clinical trial data, and molecular databases. Life science customers like Genentech and AstraZeneca are using AI agents and other generative AI tools to increase the speed of scientific discovery. Builders at these organizationsContinue Reading
In the pharmaceutical industry, biotechnology and healthcare companies face an unprecedented challenge for efficiently managing and analyzing vast amounts of drug-related data from diverse sources. Traditional data analysis methods prove inadequate for processing complex medical documentation that includes a mix of text, images, graphs, and tables. Amazon Bedrock offers featuresContinue Reading
Gam1983/iStock via Getty Images Eli Lilly (NYSE:LLY) is the weight loss drug stock with the most potential for upside, according to Seeking Alpha’s July Sentiment Survey. July’s Sentiment Survey by Seeking Alpha is out, covering what’s hot in the markets, the economy and other current themes. According to the survey,Continue Reading
JHVEPhoto/iStock Editorial via Getty Images Argus has upgraded Teva (NYSE:TEVA) to buy, citing valuation and the approval of several new products. “After several years of challenges, Teva appears to have steadied its ship, launching a range of new drugs and achieving margin growth across all of its three primary businessContinue Reading
Artur Plawgo uniQure (NASDAQ:QURE) shares traded higher premarket Tuesday after the Dutch biotech posted the latest data from its Phase 1/2 clinical trials for AMT-130, an investigational gene therapy for Huntington’s disease, a rare, inherited neurodegenerative disorder. Based on a Mar. 31 data cut of 21 patients, the company saidContinue Reading
spawns Hutchmed (NASDAQ:HCM) ADRs traded higher on Friday after regulators in China agreed to review the company’s lymphoma therapy tazemetostat, developed and sold in partnership with Ipsen (OTCPK:IPSEY). China’s National Medical Products Administration (NMPA) granted priority review for the new drug application (NDA) targeting adults with relapsed or refractory (“R/R”)Continue Reading
jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker’s revenue stream, according to BMO. Kisunla, also known as donanemab, will be priced at $32,000 per year, with each vialContinue Reading
Hailshadow/iStock via Getty Images Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease. Updating data from its Phase 3Continue Reading
Love Employee Eisai (OTCPK:ESALF) has received the rights back to antibody drug conjugate farletuzumab ecteribulin (FZEC) after Bristol-Myers Squibb (NYSE:BMY) ended a strategic collaboration on the candidate. The Japanese pharma said it will accelerate development of the asset on its own. Eisai (ESAIY) has an ongoing phase 1 study inContinue Reading
mohd izzuan/iStock via Getty Images With the cost of prescription drugs soaring by nearly 40% over the past decade, affordability concerns have forced about a third of Americans to leave their prescriptions unfilled at the pharmacy, drug-saving platform GoodRx Holdings (GDRX) said in a report this week. According to GoodRx’sContinue Reading
